Recent Finacing
Recent Raise
RayzeBio develops tumor-targeted small-molecule and macrocyclic peptide-mimetic radiopharmaceuticals that deliver Actinium-225 and other isotopes to clinically validated solid tumor targets, advancing multiple programs and clinical trials.
